ANTI-TAU ANTIBODIES
Patent Information
- Application Number
- ARP20250100683
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-16
- Filing Date
- 2025-03-14
- Publication Date
- 2026-09-23
Claims
This description provides anti-tau antibodies, including compositions and methods for using such antibodies to treat Alzheimer's disease.
1. A full-length humanized anti-tau IgG1 antibody, characterized in that it comprises a heavy chain variable region comprising a CDR-H1, a CDR-H2, and a CDR-H3, and a light chain variable region comprising a CDR-L1, a CDR-L2, and a CDR-L3, wherein: the CDR-H1 of vH has the amino acid sequence established as sec. with ident. no.: 3; the CDR-H2 of vH has the amino acid sequence established as sec. with ident. no.: 4; the CDR-H3 of vH has the amino acid sequence established as sec. with ident. no.: 5; the CDR-L1 of vL has the amino acid sequence established as sec. with ident. no.: 8; the CDR-L2 of vL has the amino acid sequence established as sec. with ident. no.:
9. of ident.: 9; and the vL CDR-L3 which has the amino acid sequence established as the sec. with ident. number:
10.
5. A pharmaceutical composition characterized in that it comprises the anti-tau antibody of claims 1-4, and a pharmaceutically acceptable carrier.